Sterling Pharma Solutions
Chad Telgenhof has a extensive work experience in the pharmaceutical industry. Chad currently serves as the Chief Commercial Officer (CCO) at Sterling Pharma Solutions since May 2022. Prior to that, they were the Executive Vice President API Operations & Site Head at Sterling Pharma Solutions from September 2020 to May 2022.
Before joining Sterling Pharma Solutions, Chad held multiple roles at Alcami Corporation, including Executive Vice President API Operations, Interim Chief Commercial Officer, Senior Vice President Manufacturing & Laboratory Operations, Vice President Manufacturing Operations, and Vice President & Site Leader. Chad worked at Alcami Corporation from May 2015 to September 2020.
Chad also worked at Hospira as the Senior Director API Operations & Strategy from December 2013 to April 2015, and as a Plant Manager from July 2012 to December 2013. Prior to that, they served as the Director of Operations at Johnson Matthey from November 2010 to July 2012, Director of Operations at Lonza from April 2008 to November 2010, and Director of Operations at Cambrex from April 1998 to April 2008.
Chad Telgenhof started their career in the US Navy, where they served as a Petty Officer First Class from 1994 to 1998.
Chad Telgenhof holds a Bachelor of Science (BS) degree in Nuclear Engineering from Thomas Edison State University. Additionally, they pursued studies focusing on Lean Six Sigma at the University of Michigan. However, no specific information regarding the start and end years of these educational pursuits is provided.
This person is not in any offices
Sterling Pharma Solutions
1 followers
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities